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The mouth supports a diverse microbiota which provides major benefits to the host. On occasions, this
symbiotic relationship breaks down (dysbiosis), and disease can be a consequence. We argue that progress in
the control of oral diseases will depend on a paradigm shift away from approaches that have proved successful
in medicine for many diseases with a specific microbial aetiology. Factors that drive dysbiosis in the mouth
should be identified and, where possible, negated, reduced or removed, while antimicrobial agents delivered
by oral care products may function effectively, even at sub-lethal concentrations, by modulating the activity
and growth of potentially pathogenic bacteria. In this way, the beneficial activities of the resident oral micro-
biota will be retained and the risk of dysbiosis occurring will be reduced.
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C
urrently, one of the principal objectives of many
grant funding bodies is to drive the translation
of research findings into tangible public health
benefits. It is apparent during visits to general medical
practitioners that there has been considerable progress
made in this area in medicine. There are new diagnostic
tests, many of which are non-invasive, complemented by
advances in drugs, vaccines and other interventions. There
has also been progress towards assessing future risks of
disease in patients, so that treatment can be targeted to
their individual needs (personalised medicine). In contrast,
an individual attending a routine appointment at a dentist
would recognise fewer equivalent developments, either in
diagnosis or treatment. This is despite the fact that in
recent years we have seen advances in state-of-the-art
molecular approaches being applied to extend our knowl-
edge of the oral microbiome, the architecture of dental
biofilms and the complexity of the host defences, as well as
in the biochemistry of saliva and gingival crevicular fluid.
Many of the concepts being adapted and applied to
improve the diagnosis and treatment in oral biology have
been derived from recent advances in medicine. Perhaps it
is now time to accept that we need a paradigm shift away
from these approaches and recognise that plaque-related
diseases are a consequence of a dysbiosis in a normally
beneficial oral microbiome, which also might invoke an
inappropriate and damaging host response. Approaches
that are being applied to understand and treat dys-
biotic conditions that arise in other sites in the body, for
example, inflammatory bowel disease or Crohn’s disease,
may provide more relevant models for oral disease. If
we accept this premise, oral disease control could involve
more subtle approaches. For example, rather than screen-
ing for broad-spectrum antimicrobial agents (defined in
a conventional way by MIC/MBC criteria) for use in oral
care products to target particular ‘pathogens’, and which
could inflict considerable by-stander damage to the oral
microbiome, we should consider applying ecological prin-
ciples to control rather than eliminate components of the
microbiota, and identify and inhibit/remove the factors
that are driving the dysbiosis in that patient (1). Some
of the issues to consider when contemplating the control
of the oral microbiota in this way will be described briefly
in the following sections.
Key factors to consider when attempting
to control the oral microbiota
1. The oral microbiome is natural and beneficial. In
medicine, the physician is often faced with treating
an infection caused by specific micro-organisms not
normally found at that site, or by microbes that have
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colonised a site that is normally sterile. In contrast,
the mouth has a microbiome that is natural and is
essential for the normal development of the physio-
logy of the host (2). Some of the beneficial aspects
of the oral microbiota include:
- Colonisation resistance, for example, exclusion of
exogenous micro-organisms (3);
- Immunomodulatory activity, for example, down-
regulation of excessive pro-inflammatory responses
to the resident microbiota on mucosal surfaces
(4); and
- Enhancement of host defences and host physiol-
ogy, for example, the metabolism of dietary nitrate
to nitrite leads to a reduction in blood pressure, a
stimulation of mucous production, and the gen-
eration of antibacterial nitric oxide (5).
Therefore, the eradication of the oral microbiome
should not be attempted as these organisms have
evolved to have a synergistic relationship with the
host. Rather, the beneficial members of the oral
microbiome should be nurtured and their relative
proportions maintained, although research is
needed to more fully characterise the composition
and metabolic functions of the resident oral
microbiota.
2. The oral microbiome exists as biofilms and microbial
communities. Micro-organisms grow on oral surfaces
in structurally and metabolically organised commu-
nities of interacting species termed biofilms (6). The
properties of these microbial communities are more
than the sum of the component organisms. The com-
bination of the oral microbiome being both a bio-
film and a microbial community makes it particularly
difficult to treat with antimicrobial agents (7). There
are a number of mechanisms whereby these complex
structures are more tolerant of inhibitors, including
restricted penetration of agents into the depths of the
biofilm, the slow growth rate and an altered pheno-
type of surface-associated microbes, and cross-
protection by neighbouring cells.
Traditionally, microbiologists have focussed on the
‘names’ of species present in a sample such as dental
plaque. Selected representative species are then grown
planktonically in pure culture to evaluate the spec-
trum of activity of antimicrobial agents using
conventional MIC/MBC read-outs as applied rou-
tinely in medical microbiology. The application of
contemporary molecular approaches to understand
and define the diversity and metabolism of the oral
microbiota is starting to challenge this approach.
The Human Microbiome project has used metage-
nomics to characterise the microbiota at several
sites around the body. When the microbial profiles
of several hundred subjects were compared, there
was a degree of heterogeneity in the individual taxa
that were recovered from any one body site, such as
the mouth, but when the samples were analysed in
terms of biochemical functions (e.g. ATP synthesis,
central carbohydrate metabolism) then a huge degree
of consistency was observed (8). The inference was
that different species can perform identical roles
in a microbial community. Therefore, a way forward
could be to consider developing assays to screen for
(a) antimicrobial agents that inhibit key metabolic
‘functions’ rather than targeting specific bacterial
species, and/or (b) prebiotics that promote the growth
of resident microbial populations with beneficial
functions.
3. There is a shift in the composition and metabolism
of the oral microbiome in disease. Numerous studies,
using either traditional culture or contemporary
molecular approaches to compare the microbiota in
biofilms from healthy surfaces with that from sites
with dental caries and periodontal diseases, have
shown that there are substantial differences in the
composition of the microbiota in disease (2). Many
of the bacteria associated with disease (often refer-
red to as ‘pathogens’) can be found in biofilms from
healthy sites, but they are present in clinically irrele-
vant numbers and at a far lower frequency (9).
Therefore, disease is due to a shift in the composi-
tion of the biofilm (dysbiosis) rather than as a result
of exogenous ‘infection’. Ideally, when a patient
presents with disease, a clinician should attempt to
determine the factors responsible for driving dys-
biosis (e.g. impaired saliva flow; poor oral hygiene;
inappropriate lifestyle, including dietary habits; pre-
sence of other risk factors), while recognising that
these could vary from patient to patient. Unless
there is an attempt to interfere with the factor(s)
driving the dysbiosis then the patient is likely to
return to the surgery suffering from further episodes
of disease (10). Thus, oral disease control requires a
holistic approach.
4. Antimicrobial paradox applies to the mouth. Oral
health care products that contain antimicrobial agents
to control plaque biofilms are required to deliver
two apparently contradictory requirements in order
to meet regulatory guidelines. These are to deliver a
relevant and measurable clinical and microbiologi-
cal benefit, while at the same time not disrupting the
natural microbial ecology of the mouth, for example,
by permitting overgrowth by opportunistic pathogens
(e.g. yeasts) or exogenous micro-organisms (11).
Most antimicrobial agents used in oral care pro-
ducts are described as being broad spectrum (see
earlier), but under the conditions of use in the
mouth (twice daily for brief periods against drug
tolerant biofilms) they are present at MIC or MBC
levels for a relatively short time, with some retained
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for many hours at sub-lethal concentrations (e.g.
metal salts, triclosan) (12). At these levels, these
agents may have an important mode of action which
is consistent with this new paradigm for oral care.
At sub-lethal concentrations, these agents can target
key virulence traits such as sugar transport/acid
production and protease activity, while also generally
slowing bacterial growth. In this way, they may have
a more selective mode of action in which they mainly
inhibit the growth and metabolism of organisms
implicated in disease while leaving those associated
with oral health relatively unaffected (1). The use
of any antimicrobial agent carries the potential for
bacterial resistance to develop, especially if used at
sub-lethal concentrations. However, there is no evi-
dence for a change in MIC to agents used in oral
care products following long-term clinical use (13!15).
Unlike the principles behind antibiotic therapy,
oral care products could function prophylactically
to stabilise the normal oral microbiota under
conditions that may otherwise predispose a site to
caries or gingivitis, thereby maintaining the benefits
derived from the resident microbiome.
In order to pursue these theories, we have initiated
in silico modelling studies to model in a biofilm the
behaviour of two distinct microbial populations that
differ in their aciduricity. This model is based on a
standard hybrid algorithm that has been widely
employed in studies of environmental biofilms, and
couples individual cells to continuous dispersed
phases within a defined environment. Our computa-
tional studies demonstrate how small changes to the
local oral environment can have a major impact on
the competitiveness of oral bacteria. The findings
can be extrapolated to show how sub-lethal inter-
ference with the fluctuations in pH in a biofilm
following dietary sugar intake can alter the propor-
tions of different groups of bacteria over time. As
shown in Fig. 1a, by varying the buffering capacity
of the plaque fluid, it was possible to modulate the
biofilm composition between a weakly acidogenic
state with a low fraction of aciduric bacteria, to a
dysbiotic state where the aciduric population domi-
nated, resulting in a lower pH and an increased risk
of enamel demineralisation. A similar trend was ob-
served when the frequency of sugar intake was in-
creased, as shown in Fig. 1b. Both of these measured
trends were a sub-lethal consequence of differential
growth between the two bacterial groups, and demon-
strated that environmental alterations, such as those
achieved by a putative external agent that reduces
the rate or frequency of fall in environmental pH,
can beneficially modulate biofilm community dyna-
mics without requiring any form of direct lethal
antimicrobial action. Full details of the model,
including a range of other perturbations that simi-
larly alter both biofilm composition and pH, can be
found elsewhere (16).
Concluding remarks
It has been argued that advances in the control of oral
diseases will require a move away from approaches that
have proved successful in many areas of medicine. This
may require a more holistic approach in which wemonitor
andmanipulate the composition andmetabolism of the oral
microbiome in order to maintain the beneficial activities
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Fig. 1. The effect of varying (a) the buffering capacity of the
plaque fluid, and (b) the frequency of dietary sugar intake,
on the proportions of non-aciduric (light grey discs) and
aciduric (black discs) populations in an in silico simula-
tion of biofilm development. (a) Increased buffering (here
achieved by lowering the effective dissociation constant from
Ka
eff"10#8 to 10#10) resulted in a higher pH during sugar
intake (vertical axis), and reduced proportions of aciduric
bacteria (horizontal axis). Image insets give representative
examples of the composition of simulated biofilms at each
end of the range sampled, where light grey (black) discs cor-
respond to non-aciduric (aciduric) bacteria, respectively. (b)
Increasing the frequency of sugar intake from once every 10 h
to once every 2 h resulted in the opposite trend, i.e. an increase
in the proportions of aciduric bacteria. Data and images were
taken after 20 days of sugar pulsing, starting from an initial
state with equal proportions of aciduric and non-aciduric
bacteria. Error bars were smaller than the symbols.
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we derive from their presence and activity, while minimis-
ing the impact of any environmental and lifestyle factors
that might lead to dysbiosis in the future.
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